2319789-82-5
2319789-82-5
Chemical Structure
Gepotidacin (S enantiomer)
Synonym(s): GSK2140944 (S enantiomer)
- CAS No.: 2319789-82-5
- Formula:C24H28N6O3
- Molecular Weight:448.52
IUPAC Name: (S)-2-((4-(((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)piperidin-1-yl)methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione
InChIKey: PZFAZQUREQIODZ-IBGZPJMESA-N
SMILES: O=C(C=NC(C=C1)=C23)N3[C@@H](CN4CCC(NCC5=CC(CCCO6)=C6C=N5)CC4)CN2C1=O
Biological Activity: Gepotidacin S enantiomer is an S enantionmer of gepotidacin.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gepotidacin (S enantiomer) | 98.27% | Gepotidacin S enantiomer is an S enantionmer of gepotidacin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GSK299423 | GSK 299423 is an antibiotic agent.GSK299423 shows potent inhibition of supercoiling by DNA gyrase from S. aureus(IC50=14 nM）and Escherichia coli(IC50=100 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GSK945237 | GSK945237 is a potent and orally active bacterial type IIA topoisomerases inhibitor. GSK945237 shows broad-spectrum activity against Gram-positive and Gram-negative bacteria (IC50 of 0.034 μg/mL against H. influenzae DNA gyrase). GSK945237 demonstrates good in vivo efficacy in a rat respiratory tract infection model. GSK945237 can be used for anti-infection research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
mTOR inhibitor-2 | mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NBTIs-IN-6 | NBTIs-IN-6 is a bacterial topoisomerase inhibitor with certain antibacterial activity. Among them, the MIC90 for fluoroquinolone-resistant MRSA was 2 μg/mL. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
YY173 | YY173 is a dual inhibitor for CDK4 and CDK6 with IC50 of 7.7 and 88 nM. YY173 inhibits the proliferation of cell Jurkat with an IC50 of 1.46 μM. YY173 can be used for synthesis of PROTAC CDK4/6 degrader 1 (HY-163786). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gepotidacin mesylate hydrate | 99.62% | Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gepotidacin hydrochloride | Gepotidacin hydrochloride is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gepotidacin (Standard) | ≥98% | Gepotidacin (Standard) is the analytical standard of Gepotidacin. This product is intended for research and analytical applications. Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NBTI 5463 | NBTI 5463 is a bacterial type II topoisomerases (topoisomerase II) inhibitor with antibacterial activity. NBTI 5463 inhibits GyrA and TopoIV in Pseudomonas aeruginosa and Escherichia coli. NBTI 5463 binds to topoisomerase II to prevent DNA cleavage and religation, inhibiting bacterial DNA replication and transcription. NBTI 5463 is promising for research of Gram-negative bacterial infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NHWL071065 | NHWL071065 is a CRBN-targeting IKZF1/IKZF3 molecular glues degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
